Combination therapy with Tenofovir DF (TDF)/ Emtricitabine (FTC) and Efavirenz leads to sustained and favourable responses in a large outpatient cohort (German TRUVADA cohort)

Viral suppression rates <50 cop/ml were similar in the intent to treat and per protocol analysis (figure 2). A total of 22 (4%), 35 (7%), and 50 (10%) patients discontinued the initial regimen at or before month 6, 12, and 18, respectively. No difference in the rate of discontinuation was detected between recipients of EFV and PI-containing regimens. Compared to PI regimens, EFV-based treatment was associated with a significantly higher likelihood of continued viral suppression at month 12 and 18 (table 3). In the multivariate logistic regression, virological success at month 12 and 18 was best predicted by use of EFV in the initial regimen (OR 2.14, 95% CI 1.06- 4.32, p=0.03 and OR 2.32, 95% CI 1.10-4.92, p=0.03). Results of a Cox proportional hazards model analyzing risk factors for virological failure (1. analysis) and discontinuation of initial regimen (2. analysis) are shown in table 4.